Bicycle therapeutics announces first patient dosed in bt8009 phase ii expansion cohorts and provides program update

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq:bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced updates from the phase i/ii trial of bt8009 in patients with numerous cancer types where nectin-4 is expressed.
BCYC Ratings Summary
BCYC Quant Ranking